Estrogen Receptor Determination Predicts Response to Tamoxifen Therapy
Tamoxifen (TAM, ICI 46,474) is a nonsteroidal antiestrogen of the triphenylethylene family. The clinical use of TAM was first reported in 1971 (Cole et al., 1971), and early clinical trials suggested that TAM was useful in the treatment of metastatic breast cancer (Cole et al., 1971; Ward, 1973; Cole et al., 1972). These studies yielded response rates ranging between 15% and 60% with minimal toxicity.
KeywordsToxicity Estrogen Shrinkage Oncol Tamoxifen
Unable to display preview. Download preview PDF.
- Breast Cancer Task Force Treatment Committee, National Cancer Institute: Breast cancer: Suggested protocol guidelines for combination chemotherapy trials and for combined modality trials. U.S. Department of Health, Education and Welfare Publication No. (NIH) 77–1192 (1977)Google Scholar
- Cole, M. P., Jones, C. T. A., Todd, I. D. H.: The treatment of advanced carcinoma of the breast with the anti-oestrogenic agent tamoxifen (ICI 46,474) — a series of 96 patients. Adv. Antimicrob. Antineoplas. Chemother. 2, 529–531 (1972)Google Scholar
- Lehmann, E. H.: Non-parametries: Statistical methods based on ranks, p. 208. San Francisco: Holden-Day Inc. 1975Google Scholar
- McGuire, W. L., Carbone, P. P., Sears, M. E., Escher, G. C.: Estrogen receptors in human breast cancer: An overview. In: Estrogen receptors in human breast cancer. McGuire, W. L., Carbone, P. P., Volmer, E. P. (eds.), pp. 1–7. New York: Raven Press 1975Google Scholar
- O’Connor, T., Rosenbaum, C., Cardellicchio, D., Cohen, J. L., Stolbach, L.: Estrogen receptor (ER) predicts tamoxifen (Tarn) response in advanced breast cancer (Br). Proc. Ann. Meet. Am. Soc. Clin. Oncol. 19, 374 (1978)Google Scholar